Safety of measles-containing vaccines in post-marketing surveillance in Anhui, China

被引：6

作者：

Meng, Fan-Ya ^{[1
,2
,3
]}

Sun, Yong ^{[3
]}

Shen, Yong-Gang ^{[3
]}

Pan, Hai-Feng ^{[1
,2
]}

Tang, Ji-Hai ^{[3
]}

Wang, Bin-Bing ^{[3
]}

Wu, Chang-Hao ^{[4
]}

Ye, Dong-Qing ^{[1
,2
]}

机构：

[1] Anhui Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Hefei, Anhui, Peoples R China

[2] Key Lab Major Autoimmune Dis, Hefei, Anhui, Peoples R China

[3] Anhui Ctr Dis Control & Prevent, Dept Immunizat & Prevent, Hefei, Anhui, Peoples R China

[4] Univ Surrey, Fac Hlth & Med Sci, Guildford, Surrey, England

来源：

PLOS ONE | 2017年 / 12卷 / 02期

基金：

英国生物技术与生命科学研究理事会;

关键词：

EVENT FOLLOWING IMMUNIZATION; CASE-DEFINITION; DATA-COLLECTION; FEBRILE SEIZURES; GUIDELINES; ELIMINATION; CHILDREN; AGE; FEVER;

D O I：

10.1371/journal.pone.0172108

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The safety of measles vaccination is of great interest and importance to public health practice and the general society. We have analyzed the adverse events following immunization (AEFIs) of currently used measles-containing vaccines (including live attenuated measles vaccine, live attenuated measles and rubella combined vaccine, live attenuated measles and mumps combined vaccine, live attenuated Measles, Mumps and Rubella Combined Vaccine) in Anhui Province, China. From 2009 to 2014, 9.9 million doses of measles-containing vaccines were administrated and 1893 AEFIs were found (191.4 per million doses), of which, 33 serious AEFIs (3.3 per million vaccine doses) were reported. 59.4% (1124 cases) were male cases, and 85.1% (1611 cases) occurred in persons aged < 1 year. 93.3% (1766 cases) occurred at the first dose of vaccination and 95.9% (1815 cases) were found within 3 days after vaccination. This study presents up-to-date data and suggests that the measles-containing vaccines used in Anhui Province of China are safe.

引用

页数：11

共 50 条

[1] Encephalopathy with measles-containing vaccines?
[J]. Reactions Weekly, 1998, 694 (1) : 5 - 5
[2] Post-marketing device safety surveillance
Vidi, Venkatesan D.
Matheny, Michael E.
Resnic, Frederic S.
[J]. CONTEMPORARY CLINICAL TRIALS, 2011, 32 (03) : 307 - 308
[3] Post-marketing safety surveillance for inactivated Enterovirus 71 vaccines in Jiangsu, China from 2017 to 2019
Gao, Jun
Tang, Fenyang
Wang, Zhiguo
Yu, Jing
Hu, Ran
Liu, Li
Kang, Guodong
[J]. VACCINE, 2021, 39 (09) : 1415 - 1419
[4] Analyzing the US Post-marketing safety surveillance of COVID-19 vaccines
Albalawi, Omar M.
Alomran, Maha, I
Alsagri, Ghada M.
Althunian, Turki A.
Alshammari, Thamir M.
[J]. SAUDI PHARMACEUTICAL JOURNAL, 2022, 30 (02) : 180 - 184
[5] Safety of Measles-Containing Vaccines in 1-Year-Old Children
Klein, Nicola P.
Lewis, Edwin
Fireman, Bruce
Hambidge, Simon J.
Naleway, Allison
Nelson, Jennifer C.
Belongia, Edward A.
Yih, W. Katherine
Nordin, James D.
Hechter, Rulin C.
Weintraub, Eric
Baxter, Roger
[J]. PEDIATRICS, 2015, 135 (02) : E321 - E329
[6] Post-immunisation fever and the antibody response to measles-containing vaccines
Perez, S. Carazo
Bureau, A.
De Serres, G.
[J]. EPIDEMIOLOGY AND INFECTION, 2018, 146 (12): : 1584 - 1592
[7] Post-marketing surveillance of the safety of levofloxacin in Japan
Yamaguchi, Hiroki
Kawai, Hitomi
Matsumoto, Takuyuki
Yokoyama, Hiroo
Nakayasu, Toshio
Komiya, Masahiro
Shimada, Jingoro
[J]. CHEMOTHERAPY, 2007, 53 (02) : 85 - 103
[8] POST-MARKETING SURVEILLANCE
ROBSON, RH
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 25 (03) : 404 - 404
[9] POST-MARKETING SURVEILLANCE
SULLMAN, SF
[J]. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1979, 72 (01) : 65 - 66
[10] Post-marketing safety surveillance for inactivated and live-attenuated Japanese encephalitis vaccines in China, 2008-2013
Wu Wendi
Liu Dawei
Li Keli
Nuorti, J. Pekka
Nohynek, Hanna M.
Xu Disha
Ye Jiakai
Zheng Jingshan
Wang Huaqing
[J]. VACCINE, 2017, 35 (29) : 3666 - 3671

← 1 2 3 4 5 →